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Purpose. Model compounds containing NO-donor furoxan moieties
at the 3-positioned basic lateral chain of 1, a 1,4-dihydropyridine
related to nicardipine, were synthesized in order to study their vaso-
dilating activity as well as their basic and lipophilic behaviour.
Methods. All the compounds were obtained by a modified Hantzsch
approach. Potentiometry was used to determine pKa and lipophilicity
descriptors. The furoxan 4-aryl-1,4-dihydropyridines were assessed
for their ability to release nitrite, in the presence of a large excess of
cysteine, by the Griess reaction. Vasodilating activity of the products
in the absence and in the presence of ODQ, a well-known guanylate
cyclase inhibitor, was evaluated on rat thoracic aorta.
Results. The compounds display low basicity values and for this rea-
son their log Ds at physiological pH are identical to the log Ps of the
neutral forms. Products 2, 3 display vasodilating action principally
dependent on their Ca2+-antagonist properties, whereas 4 behaves as
a well-balanced hybrid with mixed Ca2+-channel blocker and NO-
dependent vasodilator activities.
Conclusions. Nitrogen containing lateral chain at the 3-position of 1
is a suitable molecular region to be modified in order to obtain well-
balanced furoxan NO-donor 1,4-DHPs. This manipulation produces a
decrease in the basicity. General analysis of pKa and lipophilicity
descriptors of these new DHPs suggest that molecular flexibility
could influence both their basicity and log PI.
KEY WORDS: 1,4-Dihydropyridines; nitric oxide (NO); NO do-
nors; hybrid drugs; furoxans.
INTRODUCTION
Recently a research program was started in our labora-
tory aimed at obtaining new “hybrid” 1,4-dihydropyridines
(1,4-DHPs) endowed with mixed nitric oxide (NO)-like and
Ca2+-channel antagonist vasodilating properties. Nifedipine
was first selected as a model for the development of these new
drugs. We substituted the o-nitro group with o- and m-
positioned furoxan moieties at the 4-phenyl ring, gifted with
different NO-releasing property (1). In a further study these
same substructures were introduced at the 3-positioned chain
of the lead (2).
We have now undertaken the study of basic NO-donor
1,4-DHPs obtained by introducing NO-donor furoxan sys-
tems on the nitrogen lateral chain of product 1, whose struc-
ture is related to nicardipine. The furoxan ring bears suitable
substituents chosen for modulating its ability to release NO to
obtain well-balanced hybrids. The NO-donor moieties were
joined to the nitrogen in the lateral chain by a spacer selected
on the basis of the synthetic accessibility of the final models.
In this preliminary communication we report synthesis,
NO-release, and vasodilating activity of the new products 2, 3,
and 4. We also evaluated their pKa and log D, tools useful for
the next pharmacokinetic study.
MATERIALS AND METHODS
Synthesis
Melting points were measured on a Bu¨chi 530 capillary
apparatus and are uncorrected. Melting points with decom-
position were determined after introducing the sample into
the bath at a temperature 10°C lower than the melting point.
A heating rate of 3°C min−1 was used. Infrared spectroscopy,
1H and 13C nuclear magnetic resonance at 200 MHz and 50
MHz, respectively, and mass spectroscopy routinely checked
the compounds. All the spectra were in accordance with the
expected structures. Column chromatography was performed
on silica gel (Merck Kieselgel 60, 230–400 mesh ASTM,
Merck, Milan) with the indicated solvent system. Petroleum
ether 40°–60°C (PE) was used. Solvent removal was achieved
under reduced pressure at room temperature. Elemental
analyses of the new compounds were performed by REDOX
(Cologno Monzese) and the results were within ±0.4% of the
theoretical values. Intermediates 1 (3), 5, 6 (1), 7 (5), and 8
(4), were synthesized according to procedures described in
the literature. Compound 10, 3-nitrobenzaldehyde, and meth-
yl 3-aminocrotonate were commercial reagents (Aldrich
Chemical Co., Milwaukee, WI).
General Procedure for the Synthesis of 1,4-DHPs 2, 3
The appropriate 4-bromomethylfuroxan 5 or 6 (4.8
mmol) was added to a solution of 1 (1.86 g, 4.8 mmol) in a
mixture of acetone (30 ml) and 0.5 N KHCO3 (20 ml). The
solution was stirred for 6 h and then was neutralized with 1N
HCl; the acetone was evaporated and the aqueous solution
was extracted with ethyl acetate. The dried organic phases
were evaporated, and the residue was purified by flash-
chromatography. The purified fractions were dissolved in
HCl saturated methanolic solution. Solvent removal gave the
final product as a hydrochloride. Chromatographic solvents,
yields, melting points, and analytical data were as follows:
Methyl 2-(N-methyl-N-(3-methylfuroxan-4-yl)methyl)-
aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-
pyridinedicarboxylate hydrochloride (2). Eluent: CH2Cl2/
MeOH 9.7/0.3; yield 44%; softening at 79°C decomposed at
110°C. Anal. (C23H27N5O8zHClz0.5H2O) C, H, N.
Methyl 2-(N-methyl-N-(3-carbamoylfuroxan-4-yl)-
methyl)aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitro-
phenyl)-3,5-pyridindicarboxylate hydrochloride (3). Eluent:
CH2Cl2/MeOH 9.9/0.1fi 9.7/0.3; yield 84%; softened at 135°C
and then slowly decomposed until 151°C. Anal.(C23H26N6O9z
HClzH2O) C, H, N.
4-(2-(N-(2-Hydroxyethyl)-N-tert-butoxycarbonylamino)-
ethyloxy)-3-phenylsulfonylfuroxan (9)
Fifty percent NaOH (3.28 g, 41 mmol) was added drop-
wise to a solution of 7 (12.44 g, 34 mmol) and 8 (7.02 g, 34
mmol) in THF (100 ml) at −5°C. The mixture was stirred at
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−15°C for 2.5 h, then phosphate buffer (pH 5.4, 0.5 M, 100 ml)
was added and the solution obtained was extracted with
CH2Cl2. The dried organic phases were evaporated and the
residue was purified by flash-chromatography (eluent: PE/
EtOAc 8/2). The purified product was an unstable oil that was
immediately used for the preparation of the intermediate 11.
The yield was quantitative.
N-(2-(3-Phenylsulfonylfuroxan-4-yloxy)ethyl)-N-tert-
butoxycarbonyl-2-aminoethyl acetoacetate (11)
A solution of 9 (2.06 g, 4.8 mmol) and 2,2,6-trimethyl-
4H-1,3-dioxin-4-one (10) (0.68 ml, 4.8 mmol) in toluene (20
ml) was refluxed for 1 h. Solvent removal gave a residue,
which was purified by flash chromatography (eluent: PE/
EtOAc 7/3). Yield 60%, oil. Anal. (C21H27N3O10S) C, H, N.
Methyl N-(2-(3-phenylsulfonylfuroxan-4-yloxy)ethyl)-N-
tert-butoxycarbonyl-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-
(3-nitrophenyl)-3,5-pyridinedicarboxylate (12)
A solution of 11 (3.50 g, 6.8 mmol), 3-nitrobenzaldehyde
(1.03 g, 6.8 mmol), and methyl 3-aminocrotonate (0.78 g, 6.8
mmol) in 2-propanol (80 ml) was refluxed for 10 h. Solvent
removal gave a residue, which was purified by flash chroma-
tography (eluent: PE/EtOAc/MeOH 7/2.5/0.5). The product
obtained was a yellow solid. Yield 51%, softened at 79°C
decomposed at 105°C. Anal.(C33H37N5O13S) C, H, N.
Methyl 2-(N-(2-(3-phenylsulfonylfuroxan-4-
yloxy)ethyl)aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-
nitrophenyl)-3,5-pyridinedicarboxylate hydrochloride (4)
HCl saturated diethyl ether was added to a solution of 12
in dry CH2Cl2 and the mixture was stirred for 48 h. Solvent
removal gave a residue that was triturated with dry diethyl
ether, filtered, and dried. Yield 66%; darkening at 115°C,
decomposed at 130°C. Anal. (C28H29N5O11SzHClz0.5H2O) C,
H, N.
pH-Metric Approach to Obtain pKa and Log P
Potentiometric titrations of compounds (1–4) were per-
formed with the GlpKa apparatus (6,7) (Sirius Analytical In-
struments Ltd, Forrest Row, East Sussex, UK). Ionization
Fig. 1. Schemes illustrating the synthesis of the compounds 2, 3 (A), 4 (B). a) 5 or 6, KHCO3 0.5N, acetone; b) HCl
saturated methanol; c) 8, 50% NaOH, THF, −15° C; d) 10, refluxed toluene; e) modified Hantzsch procedure: 3-nitro-
benzaldehyde, methyl 3-aminocrotonate, refluxed iPrOH; f) HCl saturated diethyl ether.
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constants were determined according to Ref. (8). The low
aqueous solubility of the compounds required pKa measure-
ments in the presence of methanol as a cosolvent.
To obtain lipophilicity data, at least four separate titra-
tions of ca. 0.5 mM for each compound, containing various
volumes of octan-1-ol (from 0.5 ml of organic solvent/20 ml of
H2O to 13 ml of organic solvent/7 ml of H2O), were per-
formed in the pH range 1.8 to 9. The titrations were carried
out under N2 at 25.0 ± 0.1°C (9). Final data were obtained by
the Multiset approach as described elsewhere (10) and vali-
dated by shake-flask when necessary.
RESULTS AND DISCUSSION
Chemistry
Syntheses of the 1,4-DHPs 2–4 are reported in Fig. 1.
1,4-DHPs 2 and 3 were easily obtained by stirring in acetone
in the presence of potass ium bicarbonate 2-(N-
methylamino)ethyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-
1,4-dihydropyridine-3,5-dicarboxylate (1) with 4-bromometh-
ylfuroxan 5 and 6, respectively (Fig. 1A). Synthesis of the
1,4-DHP 4 required preliminary preparation of acetylacetic
ester 11 (Fig. 1B). This intermediate was synthesized by treat-
ing 3,4-bis(phenylsulfonyl)furoxan (7) with N-Boc diethanol-
amine (8), in THF in the presence of 50% sodium hydroxide,
at −15°C. The reaction of 9 with the synthon of acetylketene
10 in boiling toluene afforded the acetylacetate 11. 1,4-DHP
12 was obtained by the reaction of 11 with m-nitrobenzalde-
hyde and methyl 3-aminocrotonate in refluxing isopropanol.
Deprotection of the nitrogen at the lateral chain with hydro-
chloric acid in diethyl ether gave the expected 1,4-DHP 4.
All the 1,4-DHPs were obtained and tested as racemic
mixtures as previously described for other NO-donor 1,4-
DHPs (2 and references therein).
All furoxan 1,4-DHPs discussed in the present work bear
a basic nitrogen chain. The pKas of compounds 2–4 (Table I)
are quite a bit lower than the pKa of the reference 1. As a
consequence, all the hybrid products, at physiological pH,
exist largely in the neutral form, unlike the lead. Such low
basicity properties are not fully explained by the presence in
the lateral chain of the strong electron withdrawing furoxan
moieties (11), with the only exception derivative 3. Simple
pKa calculations confirm this assumption (12). Indeed, intra-
molecular effects connected with molecular flexibility could
also be important in determining the basicity behavior of
these compounds.
Analysis of lipophilicity data shows that, for all the in-
vestigated compounds, there is a rather good agreement be-
tween log PN, namely the experimental lipophilicity value of
the neutral form, and the corresponding CLOGP value (see
Table I). This means that the lipophilicity behavior of the
neutral forms is not heavily influenced by intramolecular ef-
fects, which depend on the molecular flexibility not codified
in the CLOGP algorithm. All the products display quite simi-
lar log PN values with the only exception the more lipophilic
phenylsulfonyl 4. The distribution coefficient at the physi-
ological pH (log D7.4) of 1, is different from the correspond-
ing log PN, due to the high pKa value of this compound,
whereas the low basicity of the furoxan derivatives 2 and 3
renders their log PN 4 log D7.4.
Recently, the diff(log PN-I), namely the difference be-
tween the lipophilicity of neutral and ionized species of a
given compound, was successfully used (8) to investigate the
lipophilic behavior of ionized species of compounds. As a
rule, the diff(log PN-I) covers a range from 3 to 4 in the
octanol/water system. Among the diff(log PN-I) entered in
Table I, only that of 3 is in keeping. This suggests that mo-
lecular flexibility should influence the lipophilicity behavior
of the remaining cations.
NO-Release
The capacity of all the final 1,4-DHPs to produce nitrite
in physiological conditions, in the presence of an excess of
cysteine, was evaluated by the procedure previously de-
scribed (13). The results are entered in Table II. The forma-
tion of nitrite is relevant for sulfonyl derivative 4, intermedi-
ate for carbamoyl compound 3, and negligible for methyl de-
rivative 2. Detection of nitrite can be used to infer the
previous presence of NO. It can be used as a measure of the
original concentration of nitric oxide but only in a first ap-
Table I. Ionisation Constants and Lipophilic Descriptors in Octanol/water of the Compounds Under Study
Compound pKa
a CLOGPb log PN c diff(log Pexp-calc)d log PI e diff(log PN-I)f log D7.4 k
1 8.78 ± 0.04 3.06 2.86 ± 0.01 −0.20 0.35 ± 0.02 2.51 1.50
2 3.83 ± 0.04 2.84 2.86 ± 0.06g 0.02 0.85 ± 0.09h 2.01 2.86
3 5.07 ± 0.02 2.18 2.85 ± 0.02 0.67 −0.08 ± 0.02i 2.93 2.85
4 4.59 ± 0.01 5.30 — j — — — —
a Determined by potentiometry; MeOH as cosolvent was used in percentage ranging from 30 to 65. The extrapolation
to zero was obtained by the Yasuda-Shedlovsky procedure (15).
b Calculated log P values by CLOGP programme v. 4.0, BioByte Corp.
c Log P of the neutral form of the compound determined by potentiometry.
d Log PN minus CLOGP.
e Log P of the cationic form of the compound determined by potentiometry otherwise specified.
f Log PN − log PI
g Obtained by mixed procedure: potentiometry combined with shake-flask.
h Validated by shake-flask.
i Obtained by shake-flask.
j Insoluble in either water or octanol.
k Calculated from the following equation: D = PN ? S 1
1 + 10 pKa- pH
D + PI ? S 10 pKa - pH
1 + 10 pKa- pH
D
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proximation because, in these conditions, NO can undergo a
variety of reactions besides oxidation (14).
Pharmacology
Vasodilator activities of 1,4-DHPs were evaluated on K+-
depolarized rat thoracic aorta strips by the procedure previ-
ously described (1). EC50 values, calculated from concentra-
tion-response curves, are reported in Table II, as are the val-
ues in the presence of 1 mM 1H-1,2,4-oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ), a well-known inhibitor of the
soluble guanylate cyclase (sGC) (EC50
ODQ). Analysis of the
vasodilating properties (EC50, Table II) shows that introduc-
tion of furoxan substructures into the basic 3-lateral chain
affords vasodilating agents slightly more potent than the lead
1 when 3-carbamoyl (derivative 3) and 4-phenylsulfonyl (de-
rivative 4) substituted furoxan moieties are used. By using the
3-methylfuroxan substructure, the rather more potent 1,4-
DHP 2 is obtained. This last compound displays an activity
comparable to that of nicardipine.
For compounds 2 and 3, vasodilating potencies evaluated
in the presence of 1 mM ODQ are the same as those deter-
mined in its absence (Table II, EC50
ODQ). This means that in
the vasodilator response only Ca2+-channel antagonism is in-
volved. By contrast 4, which is a more potent NO-donor, in
the presence of ODQ decreases its potency by about three
times. This indicates that NO is involved in the response. No
further shift of the concentration-response curve was ob-
served on increasing the inhibitor concentration to 2 mM
ODQ. It is reasonable to assume that the vasodilating activity
retained in the presence of ODQ is principally due to its
Ca2+-channel antagonist properties (1,2). Thus, the introduc-
tion in 1 of the 3-methylfuroxan moiety and, to a lesser extent,
of the 3-carbamoyl one, is beneficial for blocking the 1,4-DHP
receptor, whereas the introduction of the 3-phenylsulfonylfu-
roxan substructure is detrimental. Analysis of the rightward
shift of the concentration-response curve of 4 (Fig. 2) shows
that the compound behaves as a well-balanced hybrid. In fact,
in a large part of the tested concentration range, it triggers
vasodilation, which depends on its NO-donor as well as its
Ca2+-blocker properties. The decrease in the ability to block
the 1,4-DHP receptor and the increase of NO-donor proper-
ties are responsible for the balance of this hybrid with respect
to unbalanced hybrids 2, 3.
In conclusion, these findings indicate that the use of
nicardipine analogue 1 as a reference model to build “hybrid”
1,4-DHPs endowed with mixed NO-like and Ca2+-channel
antagonist vasodilating properties can lead to the achieve-
ment of well-balanced hybrids when an appropriate substi-
tuted NO-donor furoxan moiety is selected. General analysis
of pKa and lipophilicity descriptors of these new DHPs sug-
gests that molecular flexibility could influence both their ba-
sicity and log PI.
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